BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23921472)

  • 21. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).
    Taylor HS; Tal A; Pal L; Li F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Du W; Hodis HN; Lobo RA; Manson JE; Merriam GR; Miller VM; Naftolin F; Neal-Perry G; Santoro NF; Harman SM
    JAMA Intern Med; 2017 Oct; 177(10):1471-1479. PubMed ID: 28846767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex hormone levels and risk of breast cancer with estrogen plus progestin.
    Farhat GN; Parimi N; Chlebowski RT; Manson JE; Anderson G; Huang AJ; Vittinghoff E; Lee JS; Lacroix AZ; Cauley JA; Jackson R; Grady D; Lane DS; Phillips L; Simon MS; Cummings SR
    J Natl Cancer Inst; 2013 Oct; 105(19):1496-503. PubMed ID: 24041978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
    Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
    JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen therapy and breast cancer in randomized clinical trials: a narrative review.
    Pan K; Lavasani S; Aragaki AK; Chlebowski RT
    Menopause; 2022 Sep; 29(9):1086-1092. PubMed ID: 35969882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen replacement therapy in women with previously treated breast cancer. ACOG Committee Opinion: Committee on Gynecologic Practice Number 135-April 1994.
    Int J Gynaecol Obstet; 1994 May; 45(2):184-8. PubMed ID: 7915695
    [No Abstract]   [Full Text] [Related]  

  • 30. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.
    Prentice RL; Chlebowski RT; Stefanick ML; Manson JE; Langer RD; Pettinger M; Hendrix SL; Hubbell FA; Kooperberg C; Kuller LH; Lane DS; McTiernan A; O'Sullivan MJ; Rossouw JE; Anderson GL
    Am J Epidemiol; 2008 Jun; 167(12):1407-15. PubMed ID: 18448442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
    Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Weiss NS; Larson EB; Rosendaal FR; Psaty BM
    JAMA; 2004 Oct; 292(13):1581-7. PubMed ID: 15467060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating the association of lactation history and postmenopausal breast cancer risk in the Women's Health Initiative.
    Stendell-Hollis NR; Thompson PA; Thomson CA; O'Sullivan MJ; Ray RM; Chlebowski RT
    Nutr Cancer; 2013; 65(7):969-81. PubMed ID: 24127779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    Byrne C; Ursin G; Martin CF; Peck JD; Cole EB; Zeng D; Kim E; Yaffe MD; Boyd NF; Heiss G; McTiernan A; Chlebowski RT; Lane DS; Manson JE; Wactawski-Wende J; Pisano ED
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study.
    Santen RJ; Yue W
    Climacteric; 2019 Feb; 22(1):3-12. PubMed ID: 30380950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
    Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
    Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.
    Jordan VC; Ford LG
    Cancer Prev Res (Phila); 2011 May; 4(5):633-7. PubMed ID: 21478501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.
    Anderson GL; Chlebowski RT; Aragaki AK; Kuller LH; Manson JE; Gass M; Bluhm E; Connelly S; Hubbell FA; Lane D; Martin L; Ockene J; Rohan T; Schenken R; Wactawski-Wende J
    Lancet Oncol; 2012 May; 13(5):476-86. PubMed ID: 22401913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
    Shufelt CL; Merz CN; Prentice RL; Pettinger MB; Rossouw JE; Aroda VR; Kaunitz AM; Lakshminarayan K; Martin LW; Phillips LS; Manson JE
    Menopause; 2014 Mar; 21(3):260-6. PubMed ID: 24045672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
    Stefanick ML; Anderson GL; Margolis KL; Hendrix SL; Rodabough RJ; Paskett ED; Lane DS; Hubbell FA; Assaf AR; Sarto GE; Schenken RS; Yasmeen S; Lessin L; Chlebowski RT;
    JAMA; 2006 Apr; 295(14):1647-57. PubMed ID: 16609086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.